CM Management LLC Purchases 15,000 Shares of Lantern Pharma Inc. (NASDAQ:LTRN)

CM Management LLC grew its position in shares of Lantern Pharma Inc. (NASDAQ:LTRN) by 8.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 200,000 shares of the company’s stock after buying an additional 15,000 shares during the quarter. CM Management LLC owned 1.86% of Lantern Pharma worth $638,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Sanctuary Advisors LLC bought a new stake in shares of Lantern Pharma in the 4th quarter worth $32,000. 28.62% of the stock is owned by institutional investors and hedge funds.

Lantern Pharma Price Performance

LTRN stock opened at $3.66 on Friday. The stock has a market capitalization of $39.47 million, a P/E ratio of -2.06 and a beta of 1.64. Lantern Pharma Inc. has a 1-year low of $2.79 and a 1-year high of $11.99. The business has a fifty day moving average price of $4.23 and a 200-day moving average price of $3.81.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.